Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam

Access More Questions

A 38-year-old woman presents with a 3.5 cm palpable mass in the left breast and ipsilateral mobile axillary lymphadenopathy. Core biopsy confirms grade 3 invasive ductal carcinoma, ER 0%, PR 0%, HER2-negative (triple-negative breast cancer). Staging CT and bone scan show no distant metastases (cT2N1M0). What is the standard neoadjuvant systemic therapy regimen?

Pembrolizumab combined with carboplatin and paclitaxel, followed by pembrolizumab with doxorubicin and cyclophosphamide Dose-dense AC followed by weekly paclitaxel without immunotherapy Docetaxel plus cyclophosphamide (TC) for 6 cycles Cisplatin plus gemcitabine for 4 cycles

Correct Answer:

Pembrolizumab combined with carboplatin and paclitaxel, followed by pembrolizumab with doxorubicin and cyclophosphamide

Access more questions from this quiz

Continue to Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam for more practice questions and the full quiz experience.

Access More Questions